drugset / Trial / NCT05165732

Safety and Immunogenicity Study of Booster Vaccination With COVID-19 Vaccine (Vero Cell),Inactivated From Different Manufactures for Prevention of COVID-19

NCT05165732

Phase 4 Suspended 480 enrolled Sinovac Research and Development Co., Ltd.
RandomizedParallel-groupOpen-labelPrevention

Summary

This is a randomized, Open, control phase Ⅳ clinical trial of inactivated COVID-19 vaccine manufactured by Sinovac Research \& Development Co., Ltd,Beijing institute of Biological Products Co.,Ltd and Wuhan Institute of Biological Products Co.,Ltd.The purpose of this study is to explore booster Immunization of SARS-CoV-2 Inactivated Vaccine from different manufactures in adults aged 18-45 years old Previously Vaccinated with inactivated COVID-19 vaccine

Timeline

Start
2022-12-20
Primary completion
2023-03-20
Completion
2023-08-20

Drugs

EvaluationDrugModalityDoseRoute
Subject CoronaVac Vaccine 600 unknown
Subject Inactivated COVID-19 vaccine manufactured by Beijing Institute of Biological Products Co.,Ltd. Vaccine 4 ug
Subject Inactivated COVID-19 vaccine manufactured by Wuhan Institute of Biological Products Co.,Ltd. Vaccine 200 unknown

Indications